全文获取类型
收费全文 | 1642篇 |
免费 | 78篇 |
国内免费 | 56篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 72篇 |
妇产科学 | 14篇 |
基础医学 | 197篇 |
口腔科学 | 26篇 |
临床医学 | 175篇 |
内科学 | 433篇 |
皮肤病学 | 56篇 |
神经病学 | 105篇 |
特种医学 | 318篇 |
外科学 | 107篇 |
综合类 | 23篇 |
预防医学 | 110篇 |
眼科学 | 5篇 |
药学 | 64篇 |
中国医学 | 2篇 |
肿瘤学 | 61篇 |
出版年
2022年 | 6篇 |
2021年 | 20篇 |
2020年 | 11篇 |
2019年 | 12篇 |
2018年 | 20篇 |
2017年 | 7篇 |
2016年 | 12篇 |
2015年 | 20篇 |
2014年 | 29篇 |
2013年 | 61篇 |
2012年 | 46篇 |
2011年 | 36篇 |
2010年 | 51篇 |
2009年 | 81篇 |
2008年 | 48篇 |
2007年 | 87篇 |
2006年 | 49篇 |
2005年 | 45篇 |
2004年 | 40篇 |
2003年 | 39篇 |
2002年 | 32篇 |
2001年 | 29篇 |
2000年 | 29篇 |
1999年 | 40篇 |
1998年 | 74篇 |
1997年 | 85篇 |
1996年 | 105篇 |
1995年 | 64篇 |
1994年 | 61篇 |
1993年 | 55篇 |
1992年 | 36篇 |
1991年 | 27篇 |
1990年 | 31篇 |
1989年 | 52篇 |
1988年 | 37篇 |
1987年 | 39篇 |
1986年 | 47篇 |
1985年 | 46篇 |
1984年 | 13篇 |
1983年 | 16篇 |
1982年 | 18篇 |
1981年 | 11篇 |
1980年 | 14篇 |
1979年 | 11篇 |
1978年 | 16篇 |
1977年 | 12篇 |
1976年 | 15篇 |
1975年 | 13篇 |
1974年 | 6篇 |
1973年 | 7篇 |
排序方式: 共有1776条查询结果,搜索用时 15 毫秒
61.
62.
63.
64.
Fermand JP; Chevret S; Ravaud P; Divine M; Leblond V; Dreyfus F; Mariette X; Brouet JC 《Blood》1993,82(7):2005-2009
Sixty-three patients with high tumor mass multiple myeloma were treated with high-dose chemotherapy and total body irradiation supported by autologous blood stem cell transplantation. After high-dose therapy, they were monitored for a median of 44 months. Seven patients died early from toxicity. All the other patients, including those whose disease was resistant to previous therapies, showed a tumor mass reduction. At 6 months postengraftment, 40 (71%) of the surviving patients had minimal residual disease and 11 (20%) were in apparent complete remission. During follow-up, 25 out of the 63 (39%) patients relapsed and 16 of these died; 31 (49%) had a sustained remission. The median overall and event-free survival times after transplantation were 59 and 43 months, respectively. The initial serum beta 2-microglobulin value (> or < 2.8 mg/L) and length of previous therapy (> or < 6 courses of chemotherapy) were the only significant prognostic factors. In all surviving patients, blood stem cell autograft provided satisfactory and sustained haematopoietic reconstitution most often within 15 days. High dose chemoradiotherapy followed by autologous blood stem cell transplantation is thus an important therapeutic option for young patients with aggressive multiple myeloma. 相似文献
65.
66.
JD Roberts JC Herkert J Rutberg SM Nikkel ACP Wiesfeld D Dooijes RM Gow JP van Tintelen MH Gollob 《Clinical genetics》2013,83(5):452-456
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited myocardial disease that predominantly affects the right ventricle and is associated with ventricular arrhythmias that may lead to sudden cardiac death. Mutations within at least seven separate genes have been identified to cause ARVC, however a genetic culprit remains elusive in approximately 50% of cases. Although negative genetic testing may be secondary to pathogenic mutations within undiscovered genes, an alternative explanation may be the presence of large deletions or duplications involving known genes. These large copy number variants may not be detected with standard clinical genetic testing which is presently limited to direct DNA sequencing. We describe two cases of ARVC possessing large deletions involving plakophilin‐2 (PKP2) identified with microarray analysis and/or multiplex ligation‐dependent probe amplification (MLPA) that would have been classified as genotype negative with standard clinical genetic testing. A deletion of the entire coding region of PKP2 excluding exon 1 was identified in patient 1 and his son. In patient 2, MLPA analysis of PKP2 revealed deletion of the entire gene with subsequent microarray analysis demonstrating a de novo 7.9 Mb deletion of chromosome 12p12.1p11.1. These findings support screening for large copy number variants in clinically suspected ARVC cases without clear disease causing mutations following initial sequencing analysis. 相似文献
67.
Ian J Majewski Lorenza Mittempergher Nadia M Davidson Astrid Bosma Stefan M Willems Hugo M Horlings Iris de Rink Liliana Greger Gerrit KJ Hooijer Dennis Peters Petra M Nederlof Ingrid Hofland Jeroen de Jong Jelle Wesseling Roelof JC Kluin Wim Brugman Ron Kerkhoven Frank Nieboer Paul Roepman Annegien Broeks Thomas R Muley Jacek Jassem Jacek Niklinski Nico van Zandwijk Alvis Brazma Alicia Oshlack Michel van den Heuvel René Bernards 《The Journal of pathology》2013,230(3):270-276
68.
69.
Nynke D Scherpbier-de Haan Gerald MM Vervoort Chris van Weel Jozé CC Braspenning Jan Mulder Jack FM Wetzels Wim JC de Grauw 《The British journal of general practice》2013,63(617):e798-e806
Background
Chronic kidney disease (CKD) is highly prevalent in patients with diabetes or hypertension in primary care. A shared care model could improve quality of care in these patientsAim
To assess the effect of a shared care model in managing patients with CKD who also have diabetes or hypertension.Design and setting
A cluster randomised controlled trial in nine general practices in The Netherlands.Method
Five practices were allocated to the shared care model and four practices to usual care for 1 year. Primary outcome was the achievement of blood pressure targets (130/80 mmHg) and lowering of blood pressure in patients with diabetes mellitus or hypertension and an estimated glomerular filtration rate (eGFR)<60ml/min/1.73m2.Results
Data of 90 intervention and 74 control patients could be analysed. Blood pressure in the intervention group decreased with 8.1 (95% CI = 4.8 to 11.3)/1.1 (95% CI = −1.0 to 3.2) compared to −0.2 (95% CI = −3.8 to 3.3)/−0.5 (95% CI = −2.9 to 1.8) in the control group. Use of lipid-lowering drugs, angiotensin-system inhibitors and vitamin D was higher in the intervention group than in the control group (73% versus 51%, 81% versus 64%, and 15% versus 1%, respectively, [P = 0.004, P = 0.01, and P = 0.002]).Conclusion
A shared care model between GP, nurse practitioner and nephrologist is beneficial in reducing systolic blood pressure in patients with CKD in primary care. 相似文献70.
Arpita Kulshrestha Vasundhra Bhandari Rupkatha Mukhopadhyay V. Ramesh Shyam Sundar Louis Maes Jean Claude Dujardin Syamal Roy Poonam Salotra 《Parasitology research》2013,112(2):825-828
Simple, cost-effective approach for routine surveillance of parasite susceptibility to antileishmanial drug miltefosine (MIL) is highly desirable for controlling emergence of drug resistance in visceral leishmaniasis (VL). We validated a simple resazurin-based fluorimetric assay using promastigotes to track natural MIL tolerance in Leishmania donovani parasites from VL cases (n?=?17) against standard amastigote assay, in two different labs in India. The inter-stage MIL susceptibility correlated strongly (r?=?0.70, p?=?0.0018) using J774.A.1 macrophage cell line-based amastigote assay and fluorescence-based resazurin assay for promastigotes. Investigation of inter-stage MIL susceptibility for the same set of clinical isolates in another lab also showed a strong correlation (r?=?0.72, p?=?0.0012) using mouse peritoneal macrophages for amastigote assay and resazurin-based alamar blue assay for promastigotes. Additionally, parasites from post-kala-azar dermal leishmaniasis (PKDL) lesions (n?=?7, r?=?0.78, p?=?0.046) and MIL-induced parasites (r?=?0.92, p?=?0.0001; n?=?3) also exhibited a strongly correlated inter-stage miltefosine susceptibility. Thus, our results support the utility of resazurin assay as a simplified biological tool for MIL susceptibility monitoring in clinical isolates from MIL-treated VL/PKDL patients. 相似文献